Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin

BACKGROUND: Although pemetrexed, a potent thymidylate synthase (TS) inhibitor, enhances the cytoytoxic effect of platinum compounds against malignant pleural mesothelioma (MPM), novel combinations with effective targeted therapies are warranted. To this end, the current study evaluates new targeted...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Giovannetti, E, Zucali, P A, Assaraf, Y G, Leon, L G, Smid, K, Alecci, C, Giancola, F, Destro, A, Gianoncelli, L, Lorenzi, E, Roncalli, M, Santoro, A, Peters, G J
פורמט: Artigo
שפה:Inglês
יצא לאור: Nature Publishing Group 2011
נושאים:
Translational Therapeutics
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3242521/
https://ncbi.nlm.nih.gov/pubmed/21970874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.400
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים